K. Parikh

发表

Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity

Jipan Xie, P. Hodgkins, E. Wu, 2012, Journal of medical economics.

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

Eric Q. Wu, L. J. Wei, D. DeAngelo, 2011, Current medical research and opinion.

Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint.

S. Srinivasan, J. Tuscano, T. Facon, 2020, Clinical lymphoma, myeloma & leukemia.

Stroll in an Autumn Park

Candice L. Garwood, H. Campbell, T. Taylor, 2011 .

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.

S. Ailawadhi, Shien Guo, S. Abouzaid, 2017, Clinical therapeutics.

Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.

R. Wade, M. Hussein, Chi-Chang Chen, 2017, Journal of managed care & specialty pharmacy.

Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.

T. Delea, D. Madduri, A. Chari, 2020, Future oncology.

Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.

A. Chari, S. Abouzaid, K. Parikh, 2019, Clinical lymphoma, myeloma & leukemia.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Jipan Xie, E. Wu, A. Guo, 2011, Journal of managed care pharmacy : JMCP.

Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.

P. Hari, A. Agarwal, S. Abouzaid, 2019, Future oncology.

Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Clinical therapeutics.

Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study

R. Ben-Hamadi, Jipan Xie, E. Wu, 2010, Journal of medical economics.

Assessing the Effect of Adherence on Patient‐reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma

Shaloo Gupta, R. Liebert, S. Abouzaid, 2018, Clinical lymphoma, myeloma & leukemia.

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.

Jipan Xie, Zheng-Yi Zhou, Zhou Zhou, 2019, Blood advances.

Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database

A. Agarwal, A. Chari, S. Abouzaid, 2017 .

Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma

R. Fonseca, P. Richardson, L. Cosler, 2016 .

Trends in overall survival and costs of multiple myeloma, 2000–2014

R. Fonseca, P. Richardson, L. Cosler, 2016, Leukemia.

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

D. DeAngelo, V. Bollu, E. Wu, 2011, Current medical research and opinion.

Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity

Jipan Xie, P. Hodgkins, M. Erder, 2012, Journal of medical economics.